Skip to content
Log in
Open access

Structure-Based In Silico Screening of PubChem Compounds for Potential Anti-Inflammatory and Anticancer Targets

Mst Neha Islam Ema A. Ashraful K. Fatema Saikat Bhowmik A. K. Alam F. Hossain
Jul 2026 · Bangladesh Pharmaceutical Journal · 0 citations · 37 references

TL;DR

C25, the pyrazolin derivative represents a novel multi-target ligand with potential applications as an anti-inflammatory, analgesic, and anti-neoplastic agent and highlights its promise as a lead scaffold for future drug development.

Abstract

Multi-target treatment methods are essential because inflammation and cancer involve intricate, interrelated pathways. To screen thirty different small compounds from PubChem for potential multi-target activity, this study employed a structure-based drug design approach. Their binding affinities for key inflammatory, analgesic and carcinogenic protein targets were evaluated using molecular docking, yielding promising candidates for further experimental validation. A total of eight pharmacologically significant receptors were selected: COX-1 (3KK6), COX-2 (3LN1), MOR (4DKL), EGFR (4HJO), ERα (3ERT), AR (1E3G), HER2 (3PP0) and CDK8 (5F19) targets. Protein structures were prepared using Discovery Studio and molecular docking was performed with AutoDock Vina in PyRx. Standard drugs such as aspirin, tramadol, erlotinib, tamoxifen, bicalutamide, lapatinib and raltitrexed were used for comparative evaluation of docking scores and interaction patterns. Post-docking analysis primarily focused on key amino acid interactions, hydrophobic contacts and hydrogen bonding. Among all tested compounds, C25, was identified as the most potent and effective compound. It exhibited strong binding affinities toward 3LN1 (-10.0 kcal/mol), 3PP0 (-9.6 kcal/mol), 5F19 (-11.9 kcal/mol), 3ERT (-8.6 kcal/mol), 1E3G (-8.8 kcal/mol), 4HJO (-8.9 kcal/mol), surpassing their respective standards. Moreover, Verimol K with 3KK6 (-7.8 kcal/mol) and 8-Deoxylactucin with 4DKL (-7.5kcal/mol) showed notable activity. Overall, the pyrazolin derivative represents a novel multi-target ligand with potential applications as an anti-inflammatory, analgesic, and anti-neoplastic agent. Its strong binding affinity across multiple therapeutic targets highlights its promise as a lead scaffold for future drug development.  Bangladesh Pharmaceutical Journal 29(2): 172-192, 2026 (July)

DOI Semantic Scholar
Read PDF

Similar papers

Aug 2026

Structure-based elucidation of thiazine inhibitors targeting estrogen receptors alpha: pharmacophore modeling, virtual screening, molecular docking, MD, and DFT approach.

This research developed a promising lead molecule (HIT1) as a therapeutic approach for ER-positive breast cancer through pharmacophore model-based drug design of thiazine derivative targeting ERα via pharmacophore model-based drug design.

M. Sanjeev, Bhim Singh, Kailash Jangid et al. · 0 citations
Jul 2026

Structure-Based Design and Evaluation of Coumarin-Derived CDK4 Inhibitors for Non-Small Cell Lung Cancer: An Integrated Computational Study.

Findings establish coumarin-derived scaffolds as promising starting points for the development of next-generation CDK4-targeted therapeutics and provide a strong computational foundation for future experimental validation in NSCLC.

N. M. Arulmozhi, Thiyagarajan G · 0 citations
Open access Aug 2026

Computational Design of Novel Anticancer Agents for Lung Cancer: A Molecular Docking and ADMET Analysis

NSCLC is still one of the leading causes of cancer mortality around the world, and there is a need for new therapeutic agents to overcome the limitations of existing targeted therapies, including the development of resistance to the drugs and significant side effects. In this study, several 1,2,3-triazole hybrids based on cabotegravir were assessed in an integrated computational methodology for their potential as anticancer agents by targeting a lung cancer-associated protein (PDB ID: 2ITY). Molecular docking was performed using PyRx 0.8 to assess binding affinities. The pharmaceutical properties of the compounds were evaluated for pharmacokinetic properties and the likelihood of toxicity, using SwissADME and pkCSM, respectively, and Gefitinib was used as the reference drug. Many of the compounds had statistically superior binding energies than Gefitinib (−7.5 kcal/mol); among the compounds studied, compounds 5e, 5h, and 6d showed the best binding energies [−10.2 kcal/mol].

J. B. Kathayat · 0 citations
Aug 2026

In silico investigation of novel isatin derivatives as potential multi-target anticancer agents targeting VEGFR-2, EGFR, and caspase-6.

This study highlights the usefulness of computational approaches in the discovery of novel isatin-based multi-target lead candidates for cancer therapy and suggests that compound 4 represents a promising lead for further investigation.

Vipul Kumar, Vivek Kumar, P. C. Sharma et al. · 0 citations
Aug 2026

QSAR, molecular dynamics, and biological evaluation of novel myeloperoxidase inhibitors via ligand-based pharmacophore modeling as potential anticancer agents

The findings from molecular docking, 500-ns molecular dynamics simulations, MM-GBSA calculations, and alanine scanning analyses collectively corroborate a stable binding mode of BTB11556 within the MPO active site, support further investigation of BTB11556 as a candidate compound associated with MPO-targeted therapeutic strategies.

Maysoon Raed Alnajdawi, H. Wahab, Belal Alnajjar et al. · 0 citations
Review Open access Jul 2026

Integrated CADD, Molecular Docking and ADMET Prediction in Anti-Inflammatory Lead Discovery: A Review

Inflammation involves coordinated activation of vascular, immune, lipid mediator, cytokine, transcriptional and inflammasome pathways. Modern anti-inflammatory lead discovery increasingly uses computer-aided drug design to identify plausible protein-ligand interactions before costly laboratory studies. This review summarizes the rationale for target selection, molecular docking, ADMET prediction, toxicity screening and Quality by Design-based documentation in anti-inflammatory computational pharmacology. The article emphasizes that docking scores are hypothesis-generating outputs and must be interpreted with binding-pose quality, residue relevance, pharmacokinetic feasibility and safety prediction. Selected natural scaffolds such as curcumin, quercetin, luteolin, apigenin, resveratrol, berberine, boswellic acid, andrographolide, withaferin A, gallic acid and ellagic acid are discussed as examples of chemically diverse candidates for pathway-based screening

Vikas M. Mohanale, Dr. Ravi U. Kurhade, Dr. Manoj H. Dev, Amol S. Dhakpade, Nishinandan M. Shinde · 0 citations